ArticlebioRxiv : the preprint server for biology2026
Anti-amyloid immunotherapy drives APOE4 specific increases in glial reactivity, perivascular immune activation, and ARIA-like events.
Akhil V Pallerla, Chloe C Lucido, Kai Saito, Georgia L Nolt, Jose Arbones-Mainar, Jessica L Funnell, Diksha Satish, Lily M Smith, Isaiah O Stephens, Danielle Goulding and 10 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Akhil V PallerlaDepartment of Physiology, University of Kentucky College of Medicine, Lexington, KY.ORCID 0000-0002-9425-601X Kai SaitoSanders Brown Center on Aging, University of Kentucky, Lexington, KY.
Jose Arbones-MainarDepartment of Physiology, University of Kentucky College of Medicine, Lexington, KY.ORCID 0000-0002-8982-3737 Jessica L FunnellDepartment of Neuroscience, University of Kentucky College of Medicine, Lexington, KY.ORCID 0000-0003-1971-6028 Isaiah O StephensDepartment of Physiology, University of Kentucky College of Medicine, Lexington, KY.ORCID 0009-0007-7070-1805 Danielle GouldingSanders Brown Center on Aging, University of Kentucky, Lexington, KY.
Steven M MacLeanDepartment of Physiology, University of Kentucky College of Medicine, Lexington, KY.
Samantha M OlmstedDepartment of Neuroscience, University of Kentucky College of Medicine, Lexington, KY.ORCID 0009-0004-3018-4709 Gabriela HernandezDepartment of Neuroscience, University of Kentucky College of Medicine, Lexington, KY.
Scott PersohnStark Neurosciences Institute, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0001-5047-8238 Shannon L MacauleyDepartment of Physiology, University of Kentucky College of Medicine, Lexington, KY.ORCID 0000-0002-4292-2703 Paul R TerritoStark Neurosciences Institute, Indiana University School of Medicine, Indianapolis, IN.
Funding
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathiesP20GM148326 · NIGMS · UNIVERSITY OF KENTUCKY · PI Patrick G Sullivan · 2023 to 2026
$10.6MNRSA Training CoreTL1TR001997 · NCATS · UNIVERSITY OF KENTUCKY · PI PENDERGAST, JULIE S, STOOPS, WILLIAM WALTON · 2016 to 2025
$4.2MThe metabolic interplay of sleep and Alzheimer's diseaseR01AG068330 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MACAULEY-RAMBACH, SHANNON L · 2020 to 2024
$3.5MContributions of astrocyte RelA signaling in aging-related neurodegenerative sequelae following TBIR01AG070830 · NIA · UNIVERSITY OF KENTUCKY · PI MORGANTI, JOSH · 2021 to 2025
$3.3MAPOE Allele Switching as a Therapeutic Approach for Alzheimer's DiseaseR01AG080589 · NIA · UNIVERSITY OF KENTUCKY · PI Lance Allen Johnson · 2023 to 2026
$2.6MAssessing the role of APOE in glial lipid droplet metabolism and functionR01AG081421 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sarah Cohen, Lance Allen Johnson · 2023 to 2026
$2.4MInflammatory contributions of astrocytic RelA in comorbid VCID/ADRF1NS118558 · NINDS · UNIVERSITY OF KENTUCKY · PI MORGANTI, JOSH · 2020 to 2021
$2.4MTraining in Translational Research in Alzheimer's and Related Dementias (TRIAD)T32AG057461 · NIA · UNIVERSITY OF KENTUCKY · PI MURPHY, MICHAEL PAUL, VAN ELDIK, LINDA J · 2017 to 2021
$2.1MLactate as a regulator of Alzheimer's pathologyR01AG093847 · NIA · UNIVERSITY OF KENTUCKY · PI Shannon L Macauley-Rambach · 2025 to 2026
$1.5MNCATS NIH HHS TL1 TR001997NIA NIH HHS R01 AG068330NIA NIH HHS R01 AG070830NIA NIH HHS R01 AG080589NIA NIH HHS R01 AG081421NIA NIH HHS R01 AG093847NIA NIH HHS T32 AG057461NIGMS NIH HHS P20 GM148326NINDS NIH HHS RF1 NS118558
6 · The paper itselfAbstract
Anti-amyloid antibodies represent the first disease modifying therapeutics for Alzheimer's disease (AD). Adoption of these novel treatments has been slowed by the occurrence of amyloid related imaging abnormalities (ARIA) - treatment-associated edema (ARIA-E) or microhemorrhages (ARIA-H) that disproportionately affect carriers of the E4 allele of apolipoprotein E (
Identifiers
PMID42427668
PMCPMC13344941
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390